ASX Health Stocks: Neuroscientific announces breakthrough as Neuren gets ready for Phase 2 trial
Health & Biotech
Health & Biotech
Link copied to
The ASX 200 Health Index (XHJ) is down by 1.40% at the time of writing, compared to the broader index which is down by 0.45%.
Neuroscientific Biopharma (ASX:NSB) said studies indicated that its lead drug candidate, EmtinB, reduces key drivers of chronic inflammation and autoimmune diseases.
These inflammatory cytokines, called (IL)-17A, IL-17F and IL-6, significantly contribute to the progressive loss of neurons in Multiple Sclerosis and Alzheimer’s disease.
The reduction of the production of these cytokines when using EmtinB suggests that EmtinB could be a viable treatment for these neurodegenerative conditions.
NSB CEO, Matt Liddelow, said: “These impressive results reinforce the multi-faceted therapeutic potential of EmtinB as a disease-modifying treatment for both Multiple Sclerosis and Alzheimer’s disease.”
“EmtinB has the potential to positively influence neuroprotection, neuroregeneration, and the inflammatory environment that acts to exacerbate tissue damage in these neurodegenerative conditions,” he added.
The NSB team is now finalising all necessary activities for submission of EmtinB for review by the Human Research Ethics Committee, and expects an outcome before the end of Q1 CY22.
NSB also said it will provide more detail on the initiation of the first-in-human Phase I trial in a separate announcement in the coming weeks.
Neuren Pharmaceuticals (ASX: NEU) has received approval from the Human Research Ethics Committee for its Phase 2 clinical trial of NNZ-2591 in Angelman syndrome (AS).
The approval covers the three sites in Australia that will conduct the trial: Queensland Children’s Hospital, Sydney Children’s Hospital, and Austin Health in Victoria.
There are currently no approved medicines for AS, which is characterised by severe developmental delay and learning disabilities that become noticeable by the age of 6–12 months.
Children and adults with AS typically have balance issues, motor impairment and can have debilitating seizures.
The AS Phase 2 trial will enrol up to 20 children aged 3 to 17 years to examine safety, tolerability, pharmacokinetics and efficacy over 13 weeks of treatment with orally administered NNZ-2591. Results from the trial are expected in the first half of 2023.
“This is another important step achieved for the first clinical trial of NNZ-2591 in patients and Neuren’s first in Australia,” said Neuren CEO, Jon Pilcher.
Neuren is also awaiting clearance from the US FDA on its Investigational New Drug (IND) applications for the US-based Phase 2 trials of NNZ-2591 in Phelan- McDermid syndrome and Pitt Hopkins syndrome.
In parallel with those Phase 2 trials, Neuren is also preparing for Phase 3 development of NNZ-2591 across the neuro-developmental disorders and Prader-Willi syndrome.
The AnteoTech’s (ASX:ADO) share price has plunged by 45% this week on no news, which led to an enquiry by the ASX.
In its response today, ADO said it wasn’t aware of any material information that could affect the share price.
Yesterday, the company released an investor presentation where it discussed its patented nano-technology.